News | 28 April 2023
Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Bridging the gap between histopathology and molecular pathology
The business and product range of Ipca and that of Unichem complements each others business and product range
A special technique of jet injection is used to make vaccination almost painless and totally needleless.
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
The interaction with key Government Officials and industry leaders led to a joint exploration of possible collaboration and investments in the Healthcare ecosystem between the two countries
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Fully equipped labs with 75-member team set-up and made operational in <100 days
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Subscribe To Our Newsletter & Stay Updated
